ClinicalTrials.gg
TerminatedNCT02461134Updated Feb 4, 2025Results posted

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

A Phase 2 interventional study of Ponesimod in Chronic Graft Versus Host Disease, sponsored by Actelion. Terminated. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was terminated
Low recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Chronic graft versus host diseasre (GVHD) is a serious reaction that might occur in a person (the host) who has received cells or organs (graft) from another person because the graft attacks the host's cells. Currently there are no approved therapies for chronic GVHD in the USA, and patients with chroninc GVHD are treated with immunosuppressant drugs. T-lymphocytes (a type of white blood cells) are likely to play a role in the development of chronic GVHD. Due to the capacity of ponesimod to block the traffic of T-lymphocytes, ponesimod may be a new therapeutic approach to treat chroninc GVHD.

The main objective of this study is to assess the effectiveness and safety of several doses of ponesimod in subjects with chronic GVHD who did not respond to standard available treatments.

02

Conditions studied

  • Chronic Graft Versus Host Disease

Keywords

  • GVHD
  • ponesimod
03

In context

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

This study's enrollment of 1 is below the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.

Browse Bronchiolitis Obliterans Syndrome studies →

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted before Actelion became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Symptomatic moderate or severe chronic patients in need of a change of systemic (IS) therapy
  • Women of child bearing potential must have a negative pregnancy test and use reliable methods of

Exclusion criteria

Exclusion Criteria:

  • medical conditions including active or uncontrolled infections, new or recurrent , serious cardiac, pulmonary, or renal disease, and uncontrolled diabetes.
  • Performance Score \< 60.
  • therapies other than allowed background therapy
  • Anti-arrhythmic and heart rate lowering drugs.
  • Any other circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Ponesimod

    Study treatment consists of 3 consecutive periods: 5 mg ponesimod treatment period (including up-titration), 10 mg treatment period (including up-titration) and a 20 mg treatment period.

    Drug: Ponesimod

Interventions

  • Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.

    Also known as: ACT-128800

06

What researchers measure

Primary outcomes

  1. Change in Peripheral Absolute Lymphocyte Count From Baseline to Week 4, 8 and 12

    The primary pharmacodynamic endpoint assesses intra-subject dose response during the first 12 weeks of treatment.

    Time frame: From baseline to Week 12

Secondary outcomes

  1. Incident Rate of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    This outcome measure reports the occurrence of adverse events (AEs), and serious adverse events (SAEs) during the treatment period and the follow-up period, and AEs leading to premature discontinuation of study drug. A treatment-emergent AE is any AE temporally associated with the use of study treatment whether or not considered by the investigator as related to study treatment.

    Time frame: From the first study drug intake up to 30 days after last study drug intake (Week 24)

Other outcomes

  1. Assessment of a Partial or Complete Overall Response at Week 24

    The exploratory efficacy endpoint is based on the 2014 NIH Consensus Development Project response criteria. A complete overall response is defined as a resolution of all reversible manifestations due to chronic GVHD in each organ as defined per NIH Consensus Development Project response criteria. A partial overall response is defined as improvement in a measure for at least one organ without progression in measures for any other organ.

    Time frame: At Week 24

07

Results

Posted May 9, 2018
Limitations and caveats
The study was terminated early due to poor recruitment with 1 subject enrolled. Due to consequent lack of meaningful data, no conclusive analyses could be performed. The statistical analysis plan is obsolete and therefore not applicable.

Participant flow

11 subjects were screened at 5 different sites. 1 subject was finally recruited into the study. The study was prematurely terminated due to poor recruitment.

Participant flow — Overall Study
MilestonePonesimod
Started1
Completed0
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryChange in Peripheral Absolute Lymphocyte Count From Baseline to Week 4, 8 and 12

The primary pharmacodynamic endpoint assesses intra-subject dose response during the first 12 weeks of treatment.

Time frame:
From baseline to Week 12

No measurements were reported for this outcome.

SecondaryIncident Rate of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

This outcome measure reports the occurrence of adverse events (AEs), and serious adverse events (SAEs) during the treatment period and the follow-up period, and AEs leading to premature discontinuation of study drug. A treatment-emergent AE is any AE temporally associated with the use of study treatment whether or not considered by the investigator as related to study treatment.

Time frame:
From the first study drug intake up to 30 days after last study drug intake (Week 24)
Reported as:
Count of participants · Participants
Incident Rate of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPonesimod
Participants with AEs1
Participants with SAEs1
Participants discontinued prematurely study drug1
Other pre-specifiedAssessment of a Partial or Complete Overall Response at Week 24

The exploratory efficacy endpoint is based on the 2014 NIH Consensus Development Project response criteria. A complete overall response is defined as a resolution of all reversible manifestations due to chronic GVHD in each organ as defined per NIH Consensus Development Project response criteria. A partial overall response is defined as improvement in a measure for at least one organ without progression in measures for any other organ.

Time frame:
At Week 24

No measurements were reported for this outcome.

Adverse events

Collected over Study treatment was terminated on Day 81 and the subject was exposed to ponesimod for a total of 81 days (i.e., Day 1 to Day 81). None of the reported adverse events (AEs) were considered by the investigator to be related to the study drug. As there was only 1 patient enrolled in the study, all (S)AEs reported occur with 100% frequency.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ponesimod0/1 (0%)1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventPonesimod
GastritisGastrointestinal disorders1/1
Virus infectionInfections and infestations1/1
Haematemesis, ParainfluenzaGastrointestinal disorders1/1
Hip fractureInjury, poisoning and procedural complications1/1
Most frequent other events
Most frequent other events
EventPonesimod
Atrial flutterCardiac disorders1/1
HypertensionVascular disorders1/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ponesimod
<=18 years0
Between 18 and 65 years1
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Ponesimod
Female1
Male0
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Ponesimod
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Mar 2017, 5 months.

Results were first posted in May 2018, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2015
First posted
Jun 3, 2015
StartActual
Sep 29, 2016
Primary completionActual
Mar 2, 2017
CompletionActual
Mar 3, 2017
Results first posted
May 9, 2018
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02461134
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Jun 3, 2015
Start date
Sep 29, 2016
Primary completion
Mar 2, 2017
Completion
Mar 3, 2017
Results posted
May 9, 2018
Last update
Feb 4, 2025

Study contacts

Daniele D'Ambrosio, MD, PhD
study chair · Actelion

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponesimod

Start the discussion